Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 30  |  Issue : 1  |  Page : 128-132

CD73, a potential diagnostic marker in Egyptian patients with chronic lymphocytic leukemia


1 Department of Clinical Pathology, Menoufia University Hospitals, Shebeen El-Koam, Egypt
2 Department of Clinical Oncology, Menoufia University Hospitals, Shebeen El-Koam, Egypt

Correspondence Address:
Nahla Osman
Department of Clinical Pathology, Menoufia University, Shebeen El-Koam, 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_50_15

Rights and Permissions

Objective This work aimed to study CD73 expression in chronic lymphocytic leukemia (CLL) patients and its correlation with other disease characteristics. Background CLL is a common B-lymphoproliferative disorder, which can be diagnosed in most cases by morphology and flowcytometry. It displays heterogeneity in clinical presentation, course, and response to treatment, which is likely due to the diversity of the biological nature of the disease. Diagnostic difficulty might arise in some patients due to atypical morphology and/or immunophenotype. CD73 is an extracellular enzyme that hydrolyses adenosine monophosphate to adenosine and is expressed on a subset of T and B lymphocytes. A number of studies have shown CD73 as a contributing factor in the multistep process of carcinogenesis by inducing favorable environment for tumor growth. However, it was shown in some studies to induce apoptosis. Patients and methods CD73 expression on both B and T lymphocytes was measured in 25 cases of newly diagnosed CLL and 15 healthy controls. The levels of expression were correlated to other disease characteristics. Results CD73 expression on CD19 + B lymphocytes was significantly lower in CLL patients compared with controls (mean 3.74 vs. 29.35%, respectively, P < 0.001). CD73 expression on T lymphocytes was also significantly lower in patients compared with controls (mean 0.46 vs. 5.10%, P < 0.001). CD73 expression on T lymphocytes was significantly lower in patients with Binet stage C compared with those with earlier stages (i.e., A and B) (mean 0.15 vs. 0.68, P = 0.05). There was no significant correlation between CD73 expression on clonal B cells and B-symptoms, clinical stage, lactate dehydrogenase, or β2microglobulin. Conclusion CD73 expression is a potential diagnostic marker in CLL. This can be particularly relevant in cases with atypical immunophenotype using the current CLL scoring system. CD73 may have a role in CLL pathogenesis as low expression can lead to failure of termination of immune response with subsequent proliferation and clonal expansion of the involved clone.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed543    
    Printed1    
    Emailed0    
    PDF Downloaded90    
    Comments [Add]    

Recommend this journal